Patents by Inventor Peter E. Haroldsen
Peter E. Haroldsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260043065Abstract: Provided herein are methods of determining NAT acetylation status of a subject with 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: March 25, 2025Publication date: February 12, 2026Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 11873525Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: January 16, 2024Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11845977Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: December 19, 2023Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20230313265Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: May 23, 2023Publication date: October 5, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20230295685Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: May 23, 2023Publication date: September 21, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20230034700Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceuticaliy acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: March 4, 2022Publication date: February 2, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 11274332Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11274331Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11268128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 8, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20220042068Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20220033876Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20220033877Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 11060128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: September 1, 2020Date of Patent: July 13, 2021Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20210002693Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20210002694Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20200407772Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 1, 2020Publication date: December 31, 2020Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20200407773Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt hereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 1, 2020Publication date: December 31, 2020Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 10793893Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: June 29, 2012Date of Patent: October 6, 2020Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20140255380Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: June 29, 2012Publication date: September 11, 2014Applicant: BIOMARIN PHARMACEUTICALS, INC.Inventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
